ERBB2-CAR-Engineered Cytokine-Induced Killer Cells Exhibit Both CAR-Mediated and Innate Immunity Against High-Risk Rhabdomyosarcoma

by Michael Merker, Michael Merker, Michael Merker, Juliane Wagner, Hermann Kreyenberg, Catrin Heim, Laura M. Moser, Winfried S. Wels, Winfried S. Wels, Winfried S. Wels, Halvard Bonig, Halvard Bonig, Zoltán Ivics, Evelyn Ullrich, Evelyn Ullrich, Evelyn Ullrich, Thomas Klingebiel, Thomas Klingebiel, Thomas Klingebiel, Peter Bader, Peter Bader, Peter Bader, Eva Rettinger, Eva Rettinger, Eva Rettinger
Published 2020-10-01

Retargeting of NK-92 Cells against High-Risk Rhabdomyosarcomas by Means of an ERBB2 (HER2/Neu)-Specific Chimeric Antigen Receptor

by Leonie D. H. Gossel, Catrin Heim, Lisa-Marie Pfeffermann, Laura M. Moser, Halvard B. Bönig, Thomas E. Klingebiel, Peter Bader, Winfried S. Wels, Michael Merker, Eva Rettinger
Published 2021-03-01

The Synergistic Use of IL-15 and IL-21 for the Generation of NK Cells From CD3/CD19-Depleted Grafts Improves Their ex vivo Expansion and Cytotoxic Potential Against Neuroblastoma:...

by Annekathrin Heinze, Annekathrin Heinze, Annekathrin Heinze, Beatrice Grebe, Beatrice Grebe, Melanie Bremm, Melanie Bremm, Sabine Huenecke, Sabine Huenecke, Tasleem Ah. Munir, Tasleem Ah. Munir, Lea Graafen, Lea Graafen, Jochen T. Frueh, Jochen T. Frueh, Michael Merker, Michael Merker, Eva Rettinger, Eva Rettinger, Jan Soerensen, Jan Soerensen, Thomas Klingebiel, Peter Bader, Peter Bader, Evelyn Ullrich, Evelyn Ullrich, Evelyn Ullrich, Evelyn Ullrich, Claudia Cappel, Claudia Cappel
Published 2019-12-01

Improving Clinical Manufacturing of IL-15 Activated Cytokine-Induced Killer (CIK) Cells

by Melanie Bremm, Lisa-Marie Pfeffermann, Claudia Cappel, Verena Katzki, Stephanie Erben, Sibille Betz, Andrea Quaiser, Michael Merker, Halvard Bonig, Michael Schmidt, Thomas Klingebiel, Peter Bader, Sabine Huenecke, Eva Rettinger
Published 2019-05-01